Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acenocoumarol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | GALK1 | P51570 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acenocoumarol SCHEMBL29454369 | 1.00 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL27497093 | 1.00 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL14662100 | 0.99 | CYP2C9 (0.98) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL28086238 | 0.95 | CYP2C9 (0.90) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| SCHEMBL11700745 | 0.89 | CYP2C9 (0.81) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Phenprocoumon SCHEMBL28142123 | 0.89 | CYP2C9 (0.79) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL29400364 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL662875 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL4439794 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Warfarin SCHEMBL3689 | 0.87 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7400 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250333462-A1 | PERIOSTIN COMPOUNDS FOR THE TREATMENT OF HAEMATOLOGICAL COMPLICATIONS | CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS (DE) | 2025-10-30 | — | — | US | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250283895-A1 | METHODS FOR PREDICTING AND TREATING CHRONIC LUNG ALLOGRAFT DYSFUNCTION | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-09-11 | — | — | US | claimed |
| EP-3938040-B1 | VITAMIN K2 IN COMBINATION WITH ANTICOAGULANTS FOR USE IN TREATING MUSCLE SORENESS | LESAFFRE & CIE (FR) | 2025-05-21 | — | — | EP | claimed |
| EP-3823660-B1 | PERIOSTIN COMPOUNDS FOR THE TREATMENT OF HAEMATOLOGICAL COMPLICATIONS | UNIV DER JOHANNES GUTENBERG UNIV MAINZ (DE) | 2025-05-07 | — | — | EP | claimed |
| US-12269021-B2 | Artificial protein catalyst | GLYTECH, INC. (JP) | 2025-04-08 | — | — | US | claimed |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-01-30 | — | — | US | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| WO-2024176961-A1 | PROTEIN RECOGNIZING K-Ras GENE MUTATION CANCER | 国立研究開発法人理化学研究所 | 2024-08-29 | — | — | WO | claimed |
| US-6156770-A | Compositions of optically pure (-) norcisapride and another therapeutic agent | SEPRACOR INC.. (US) | 2000-12-05 | — | — | US | claimed |
| US-6136327-A | RACEMIC MIXTURE OF DRUG | ALZA CORPORATION (US) | 2000-10-24 | — | — | US | claimed |
| EP-1035891-A1 | STEREOSPECIFIC DELIVERY OF A DRUG USING ELECTROTRANSPORT | ALZA CORPORATION (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0951283-A1 | NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE | THE UNIVERSITY OF VERMONT (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1999027990-A2 | STEREOSPECIFIC DELIVERY OF A DRUG USING ELECTROTRANSPORT | ALZA CORPORATION (US) | 1999-06-10 | — | — | WO | claimed |
| CN-1213965-A | Use of antiarrhythmic compounds for reducing post-infarction morality | SANOFI SA (FR) | 1999-04-14 | — | — | CN | claimed |
| US-5753702-A | INHIBITORS OF NEUTROPHIL ADHESION, ANTIINFLAMMATORY | UNIVERSITY OF VERMONT (US) | 1998-05-19 | — | — | US | claimed |
| WO-1997044024-A1 | NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE | UNIVERSITY OF VERMONT (US) | 1997-11-27 | — | — | WO | claimed |
| US-5629209-A | Method and apparatus for detecting viscosity changes in fluids | BRAUN BIOSYSTEMS, INC. | 1997-05-13 | — | — | US | claimed |
| US-4334020-A | Method of producing L-glutamic acid by fermentation | AJINOMOTO COMPANY INCORPORATED (JP) | 1982-06-08 | — | — | US | claimed |